Vimta Labs (524394) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 began with stable business performance, with total income reaching Rs. 824 million and EBITDA at Rs. 252 million, maintaining a margin of 30.6%.

• PAT for Q1 FY25 was Rs. 123 million, reflecting a PAT margin of 14.9%.

• Vimta Labs operates 15 labs across India, offering services in pharma, food, diagnostics, electronics, and environment testing, and is recognized as a leader in pharma analytical, preclinical, and food testing services.

• Standalone and consolidated unaudited financial results for Q1 FY25 were reviewed and approved by the Board on July 17, 2024, with unmodified limited review reports from statutory auditors.

• Successful US FDA remote audit with no observations and a government grant of INR 40.9 million for food lab upgrades were achieved.

Financial highlights

• Q1 FY25 consolidated revenue from operations was INR 818 million, down from INR 835 million in Q1 FY24; standalone revenue was ₹801.99 million.

• EBITDA for Q1 FY25 was INR 252.1 million, nearly flat year-over-year, with EBITDA margin at 30.6%.

• PAT for Q1 FY25 was INR 123 million, up 0.7% year-over-year, with PAT margin at 14.9%.

• Basic EPS for Q1 FY25 was Rs. 5.5 (consolidated: ₹5.54), unchanged from Q1 FY24.

• CapEx for the quarter was INR 164 million; cash and equivalents stood at INR 324 million; total borrowing at INR 120-130 million.

Outlook and guidance

• Management targets INR 500 crore annual revenue by FY26, with new Hyderabad facility and capacity expansion supporting this growth.

• Initial utilization of new capacity expected at 20-30% in the first year, ramping up thereafter.

• Focus on operational excellence, hiring, technology adoption, and customer partnerships to sustain growth.

• The proposed amalgamation of EMTAC Laboratories Private Limited is underway, with NCLT exemption from meetings and no impact on Q1 FY25 financials.